Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aura Biosciences, Inc. AURA
$10.47
+$0.27 (2.55%)
На 18:05, 12 мая 2023
+186.53%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
382915013.00000000
-
week52high
24.83
-
week52low
8.13
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-1.96000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мар 2023 г. в 20:10
Описание компании
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | 19 июл 2022 г. | |
| SVB Leerink | Outperform | 23 ноя 2021 г. | |
| Evercore ISI Group | Outperform | 23 ноя 2021 г. | |
| Cowen & Co. | Outperform | 23 ноя 2021 г. | |
| BTIG | Buy | 23 ноя 2021 г. | |
| JMP Securities | Market Outperform | Market Outperform | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rich Cadmus | A | 52500 | 52500 | 19 янв 2023 г. |
| Rich Cadmus | A | 58703 | 34125 | 19 янв 2023 г. |
| de los Pinos Elisabet | A | 187500 | 187500 | 19 янв 2023 г. |
| de los Pinos Elisabet | A | 190526 | 121875 | 19 янв 2023 г. |
| De Rosch Mark | A | 65000 | 65000 | 19 янв 2023 г. |
| De Rosch Mark | A | 58635 | 42250 | 19 янв 2023 г. |
| Feder Julie B | A | 75000 | 75000 | 19 янв 2023 г. |
| Feder Julie B | A | 72985 | 48750 | 19 янв 2023 г. |
| Johnson David Michael | A | 18000 | 904 | 06 янв 2023 г. |
| Johnson David Michael | A | 17096 | 96 | 05 янв 2023 г. |
Новостная лента
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
Business Wire
27 сент 2022 г. в 07:00
BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indetermina
JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"
Benzinga
19 июл 2022 г. в 15:06
JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ: AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura is developing a targeted virus-like drug conjugate (VDC) technology platform that could establish a new standard of.
Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer
Benzinga
23 июн 2022 г. в 08:56
Aura Biosciences Inc (NASDAQ: AURA) reported data from a retrospective analysis that assessed the visual acuity after plaque radiotherapy treatment compared with prospective data in early-stage choroidal melanoma patients treated with belzupacap sarotalocan by intravitreal.
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
Business Wire
17 июн 2022 г. в 07:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced multiple presentations of data evaluating its first VDC, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma (indeterminate lesions and small choroidal melanoma (CM)). The presentations include updated safety
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
Business Wire
03 мая 2022 г. в 07:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022 Bank of America Healthcare Conference. The conference is being held in Las Vegas, Nevada and the presentation will take place on Tuesday, May 10, 2022, at 4:55 p.m. PT. A live